{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:06:20Z","timestamp":1783728380246,"version":"3.55.0"},"reference-count":17,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecol Obstet Invest"],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; To evaluate efficacy and safety of pimecrolimus cream 1% twice daily for treatment of vulvar lichen simplex chronicus (LSC). &lt;i&gt;Methods:&lt;\/i&gt; Patients in this 12-week, open-label study had biopsy-proven vulvar LSC. Inclusion criteria were patient-reported Visual Analog Scale for Pruritus Relief \u22673 (VAS-PR, 0 cm = no itching to 10 cm = severe itching) and Investigator\u2019s Global Assessment \u22672 (IGA, 0 = no disease to 3 = severe disease). Safety was evaluated by adverse event reports and pimecrolimus blood level measurements. &lt;i&gt;Results:&lt;\/i&gt; Twelve women aged 25\u201353 years were enrolled. The median pruritus score (VAS-PR) decreased from 6 (min. 4.9, max. 9.0) at baseline to 0 cm at week 4 (max. 4.2), week 8 (max. 3.1) and week 12 (max. 2.1). Seven patients reported complete resolution of pruritus by week 4. Median IGA decreased from 2.5 (min. 2, max. 3) at baseline to 0 (min. 0, max. 2) at week 12. Erythema, excoriation, and lichenification improved for all patients. Pimecrolimus blood concentration for all samples was below the limit of quantification, 0.3 ng\/ml. No adverse events were reported. &lt;i&gt;Conclusions:&lt;\/i&gt; In this exploratory study, signs and symptoms of vulvar LSC improved for all women and pimecrolimus cream showed a favorable safety profile. Larger prospective studies are needed to further evaluate pimecrolimus for treatment of vulvar LSC.<\/jats:p>","DOI":"10.1159\/000106487","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T14:15:44Z","timestamp":1185545744000},"page":"180-186","source":"Crossref","is-referenced-by-count":25,"title":["Pimecrolimus Cream 1% for Treatment of Vulvar Lichen Simplex Chronicus: An Open-Label, Preliminary Trial"],"prefix":"10.1159","volume":"64","author":[{"given":"Andrew T.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parneix-Spake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogera L.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara J.","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2007,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1396-0296.2004.04002.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0029-7844%2802%2902080-X"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000247402"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2133.2003.04934.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053%2Fsder.2001.29066"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007%2Fs004030050343"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2001.116865"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1067%2Fmjd.2002.122187"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaad.2004.06.010"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.131.12.1403"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2004.08.015"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2133.2001.04076.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jpag.2003.11.013"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1542%2Fpeds.110.1.e2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159%2F000078462"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080%2F09546630410033781"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2005.04.006"}],"container-title":["Gynecologic and Obstetric Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/106487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/106487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:38:51Z","timestamp":1745462331000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000106487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000106487","archive":["Portico"],"relation":{},"ISSN":["0378-7346","1423-002X"],"issn-type":[{"value":"0378-7346","type":"print"},{"value":"1423-002X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}